HomeCompareLYPHF vs GBDC

LYPHF vs GBDC: Dividend Comparison 2026

LYPHF yields 529.73% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.50M in total portfolio value· pulled ahead in Year 7
10 years
LYPHF
LYPHF
● Live price
529.73%
Share price
$0.38
Annual div
$2.00
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$351.3K
Annual income
$921.47
Full LYPHF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — LYPHF vs GBDC

📍 GBDC pulled ahead of the other in Year 7

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodLYPHFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, LYPHF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
LYPHF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

LYPHF
Annual income on $10K today (after 15% tax)
$45,027.15/yr
After 10yr DRIP, annual income (after tax)
$783.25/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,982,340.51/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of LYPHF + GBDC for your $10,000?

LYPHF: 50%GBDC: 50%
100% GBDC50/50100% LYPHF
Portfolio after 10yr
$10.60M
Annual income
$8,225,827.66/yr
Blended yield
77.60%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

LYPHF
No analyst data
Altman Z
1.5
Piotroski
6/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

LYPHF buys
0
GBDC buys
0
No recent congressional trades found for LYPHF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricLYPHFGBDC
Forward yield529.73%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%51.1%
Portfolio after 10y$351.3K$20.85M
Annual income after 10y$921.47$16,450,733.83
Total dividends collected$211.1K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: LYPHF vs GBDC ($10,000, DRIP)

YearLYPHF PortfolioLYPHF Income/yrGBDC PortfolioGBDC Income/yrGap
1$37,187$26,486.56$12,492$1,791.70+$24.7KLYPHF
2$85,815$46,025.42$16,527$3,160.58+$69.3KLYPHF
3$141,454$49,631.95$23,588$5,904.90+$117.9KLYPHF
4$189,585$38,229.58$37,141$11,901.65+$152.4KLYPHF
5$226,799$23,942.82$66,205$26,463.38+$160.6KLYPHF
6$256,060$13,384.38$137,452$66,612.65+$118.6KLYPHF
7← crossover$281,045$7,061.29$342,372$195,298.53$61.3KGBDC
8$304,340$3,621.64$1,053,292$686,954.33$749.0KGBDC
9$327,476$1,832.63$4,111,439$2,984,416.95$3.78MGBDC
10$351,321$921.47$20,849,974$16,450,733.83$20.50MGBDC

LYPHF vs GBDC: Complete Analysis 2026

LYPHFStock

Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian and breast cancer; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers and other solid tumors; and Xuezhikang, a lipid regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Rivastigmine Transdermal Patch for the treatment of Alzheimer's disease; Fentanyl Transdermal Patch for cancer pain; Buprenorphine Transdermal Patch for chronic pain; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders, In addition, the company offers Rykindo, an injection for the treatment of schizophrenia; Tiandixin used as an adjuvant therapy for malignant tumors, hydrothorax and ascites, and respiratory infections; Yitaida for acute promyelocytic leukemia and liver cancer; Lutingnuo, a glutathione injection for toxicity and injuries caused by ionizing radiation; and Beitangning, a pioglitazone hydrochloride capsule to control blood glucose. Further, it offers Nuosen for acute upper digestive tract hemorrhage; Sailimai for the treatment of diarrhea; Apleek Transdermal Patch for contraception; Sidinuo for osteoporosis; Glucosamine hydrochloride tablets for osteoarthritis; Oulai, a compound sodium aescinate gel for local swelling; Oukai for the treatment of soft tissue swelling and venous edema; and Fengshiye for patients who have pains in bones, joints, and limbs. The company distributes and sells pharmaceutical drugs; and manufactures and sells biopharmaceutical products. Luye Pharma Group Ltd. was founded in 1994 and is headquartered in Yantai, the People's Republic of China.

Full LYPHF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this LYPHF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

LYPHF vs SCHDLYPHF vs JEPILYPHF vs OLYPHF vs KOLYPHF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.